‘Are my medicines really necessary?’

New icon114x114

‘Are my medicines really necessary’ is one of the most frequent questions from our patient led clinical education sessions.

In this blog Steve Turner, Head of Medicines & Prescribing @MedicineGov,  reflects on the need to combine research and guidleines with the patient’s actual experience, when deciding on medicines.


My experiences and learning

I was speaking about the use of medicines at a conference when I mentioned that medicines are ‘over prescribed’. Although nobody questioned and challenged me on this I was troubled by my use of this expression. By saying medicines are prescribed too frequently it seems to me this can be interpreted as a bad reflection on the prescribers.

As I mentally mulled this over (I’m not a quick thinker) I came to the conclusion that a beter expression may be ‘medicines are overused’. After all it’s us (the patients) who go to our Doctors, Pharmacists and Nurses and us who accept their prescriptions. Therefore if we agree that people can rely too heavily on medicines, and there’s wealth of evidence for this, then we need to sort this out together.

My social enterprise company’s Patent Led Clinical Education work came about because a large section of the population are prescribed multiple medicines, with potential for interactions and increased side-effects.

It’s widely accepted that 50% of the population don’t take their medicines as prescribed. Add to this the sometimes overlooked fact that people also use alternatives including over the counter medicines, herbal medicines , suplements, illicit drugs, self-medicate with alcohol, buy medicines over the internet, or borrow medicines from other people.

‘The human and financial costs of over use of medicines are immense. ‘

In our patient led clinical education sessions we have learned that many people don’t know what their individual medicines are for, and we see how many medicines are prescribed purely to counteract the side-effect of another medicine can pile up.

‘So far, nobody who has attended one of our sessions has expressed a wish to take more medicines, and those who did express a view all said that they didn’t want to take medicines if they didn’t have to.’

So what can we do together?

This blog aims to help us make sense of the vast amount of guidance available and describing why ‘trusted information’ is important in making decisions about medicines, and why this is only helpful it it’s linked to the patient’s actual experience.

So much information, so many policies & guidance?

There’s an overwhelming amount of information and guidance on medicines, coming out on a daily basis. Even clinicians struggle to keep up and need help.

Two things are important in trying to make sense of this information overload.

  1. Making sure that the information you are looking at is from a ‘trusted’ source, (by this I mean ones that your prescriber is expected to use). see
  2. Linking this to patient experiences and support from others who have the same conditions.


  1. ‘Trusted’ information

The National Centre for Heath and Care Education [NICE] in England produces guidance, standards, indicators and evidence services covering health and social care. It’s not just about medicines. There’s a massive amount of trusted information on their web site, which covers:

  • Conditions and diseases
  • Health protection
  • Lifestyle and wellbeing
  • Population groups
  • Service delivery, organisation and staffing

To get a feel for this one place to start is the NICE Pathways, where you can browse the topics, pick one and have the information presented in a diagram, where you can click on the headings for more information.

In some areas has been a move away from producing guidelines on a single illness or condition to a more holistic person based approach. This better reflects the complexities of real life, where it would often be a luxury to have just one illness with no complicating factors. NICE guidance on medicines optimisation, multi-morbidity clinical assessment and management, and patient experience in adult NHS services are good examples.

In addition NICE produces a document on Key Therapeutic Topics as part of the NICE Medicines and Prescribing Programme. This document is reviewed and refreshed annually. Click here for the topic list.


2. Patient experiences

Medicines (for adults) are tested and approved before that can be prescribed, and their safety is monitored, especially in the early stages, or if there are concerns (black traingle drugs). However drug trials are most often carried out on relatively small groups of poeple, usually from a limited range of ethnic groups, who who do not necessarily represent the population as a whole. For example, these ‘controlled trials’ usually exclude people with multiple illnesses, heavy drinkers or smokers, older people, and people with other illensses such as addiction or mental ill health.

Controlled drugs trials are not carried out on children.

In addition the effect of medicines, including side-effects fall into two categories. Firstly, those that can be predicted (pharmaco dynamic effects – that the effect of the drug on the body). Secondly, those that vary according to the bodily make up of the patient (called pharmacokinetic effects – the effect of the body on the drug).

It’s only when you combine the guidance with the specific circumstances of the patient, including the ethnicity and physical make up and lifestyle of the patient that a decision on a medicine can be made effectively. For this to work, the patient must be part of this decision, and be allowed to lead on their own care. Our work shows this:


Testimonials on our patient led clinical education work.

tseUCsaH.jpg small


Managing long term pain. A NICE Key Therapeutic Topic.

Medicines optimisation in long-term pain.


‘#jargonbuster ‘Medicines Optimisation’ means getting the medicines right for the individual. This may involve an alternative medicine, an alternative treatment or approach, and / or not taking medicines. The person’s experience, beliefs and what matters to them most should drive this decision, with clinicians providing guidance, advice and education on trusted sources of information, the evidence base and on safety’. (Steve Turner)


This is a brief summary relating to a topic in  the 2018 update of Medicines optimisation: key therapeutic topics

To access the pain management topic [KTT21] click here.

The section on medicines optimisation in long term pain contains a huge amount of information, including links to numerous other documents, on an areas critical to patient safety & wellbeing.

Key points:


  • There is little evidence that opioids are helpful for long-term pain.
  • Patient safety incidents relating to the unsafe doses of opiates remain a major concern. People develop a ‘tolerance’ to opiate medicines, meaning that higher and higher doses may be needed to deliver the same effect. However this tolerance rapidly goes away when the opiates are stopped, so restarting at the old dose may be fatal.


This image is taken from: ‘Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain.


Click on the image to enlarge it.



‘A review of medicines-related safety incidents involving controlled drugs reported to the NRLS over 7 years found the risk of death with controlled drug incidents was significantly greater than with medication incidents generally (odds ratio 1.48, 95% CI 1.02 to 2.17). Incidents involving overdose of controlled drugs accounted for 89 (70%) of the 128 incidents reporting death or severe harm. Five controlled drugs (morphine, diamorphine, fentanyl, midazolam and oxycodone) were responsible for 113 (88%) of these 128 incidents.’


Non-opioid medicines in long-term pain

  • Patients can be prescribed gabapentin or pregabalin for certain types of pain. Both of these medicines can lead to dependence and may be misused or diverted.

#jargonbuster ‘diverted’ = passed on or sold one to someone else.


Finally, emotional influences are real:

  • When assessing pain with someone it’s vital that clinicians take all aspects of the person’s life into account, including lifestyle, nutrition, hydration, social and housing factors, safeguarding, sleep and rest, other illnesses, emotional influences and their mental health.

And take a full history of medicines being taken, or recently stopped, including over the counter medicines, internet bought medicines, borrowed medicines and illicit substances.

Overall key points to remember on pain management:

  • Adopt a  holistic patient-centered approach

  • Aim to prevent acute pain becoming chronic pain

  • There is little evidence that opioids are helpful for long-term pain

Related Guidance:

NICE Guidance NG5 Medicines Optimisation

NICE Guidance CG76 Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence

NICE Guidnace CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings

NICE Guidance NG59 Low back pain and sciatica in over 16s: assessment and management

Opioids Aware: A resource for patients and healthcare professionals to support prescribing of opioid medicines for pain

NICE Guideline NG46 Controlled drugs safe use and management

NICE Guidance CG140 Palliative care for adults: strong opioids for pain relief


Steve is a nurse prescriber, Head of Medicines and Prescribing for @MedicineGov , Associate Lecturer at Plymouth University  and NICE Medicines and Prescribing Programme Associate.

mlkU-KY6.jpg large


Author: Steve Turner

First published 1/8/2017. Revised and updated 13/12/2018


Managing medicines in care homes – four top tips –


Managing medicines in care homes – implementing Quality Standards.

This blog is designed to provide information for care homes and for those choosing a  care home.

In a previous blog I looked at the implications of implementing the NICE Guideline on Managing Medicines in Care Homes.

As with all my posts this is  a ‘rolling blog’. I welcome feedback and comments. I will take into account all feedback and use the blog to share new learning. If I’ve missed anything or I am wrong on something I will admit it, and share the learning. Please comment via twitter @MedicineGovSte or by email to: .

Some tips:

1. Care Homes must have a medicines policy that is regularly reviewed.

It’s worth considering how your policy links to staff training and how user friendly it is. Are procedures outlined clearly in the policy, do they link to competency assesments and do you use checklists?

For example, we recently helped a care home produce a checklist on the key information needed when contacting a doctor. It is based on the SBAR (situation-background- assessment-recommendation) principle to help focus on the key information. This is proving popular as it saves time on the ‘phone, and the structured approach is popular with GPs. Staff commeted that its has saved them hours of chasing, has improved responsiveness & their realtionship with local services.

Here’s our method of working. It’s not rocket science and it works. I recommend this approach. (Click here to find out more).


2. People must have an accurate listing of their medicines on the day they transfer to the care home.

This is an area where care home staff are dependent on others. Hours can be spent trying to sort out problems. My advice here is for managers to ensure that discrepancies are always reported back to the source (in writing), and ask for feedback on how they are followed up. Additionally it’s helpful to record your satisfaction with good quality and complete discharge information.

Our experience is that can electronic systems greatly improve quality of this information.

An NHS Patient Safety Alert highlights the importance of communication of discharge information.

3. People who live in care homes should have at least 1 multidisciplinary medication review per year.

There is considerable variation in practice around medicines reviews, with increasing help available from Clinical Commissioning Group Medicines Management Teams and Specialist Clinicians in most areas.

Although this is an area largely outside the control of care homes there are 3 things which can help.

  • Firstly, by consistently referring back any prescriptions which don’t have complete and unambiguous directions.
  • Secondly, by ensuring that there is an easily accessible record of what each medicine is being prescribed for, (regular medicines, one-off prescriptions and as required medicines). I am still amazed that this isn’t always the case.
  • And thirdly, whilst staff residents / relatives are not expected to be experts on medicines, access to basic information the each medicine, including on side-effects and interactions should be readily available (see www, ).

4. Ensure you have safe systems for administering and recording medicines.

It is vital that you have a relaible and auditable system of MAR [medicine administration record] charts in place and that the process of administration of medicines to residents  is safe.

Two main points spring to mind:

4.1. MDS vs OPD. Seeing beyond misleading information about methods  administering medicines in residentail settings.

There has been a recent move by some of Pharmacies to change residential homes from Monitored Dose Systems [MDS] (also called blister packs) back to Original Pack Dispensing [OPD] (sometimes referred to as ‘patient pack dispensing’). The reason for this is often given as to improve safety. It is sometimes implied that guidelines are driving this move back to original pack dispensing, even that OPD can help prevent polypharmacy & reduce medicines waste. All of these statements are misleading.

Interestingly, the cost to the Pharmacy of  putting the medicines in MDS blister packs  is not mentioned in their promotions original pack dispensing [OPD].

I have not been able to find any evidence that original pack dispensing is safer than monitored dose systems. Additionally the related NICE guidelines, quality standards and the CQC report ‘Medicines in Health and Social Care’ do not state this.

What’s important is that the home uses the safest system of delivering the medicines to the residents, taking into account the patients’ wishes, the home’s skill mix, staff competencies, workload and capacity. This is particularly important as staff tell me original pack dispensing takes ‘twice as long’.

I am also aware of problems with OPD, for example: ‘Care home receives a box of meds. The medication is checked in and the resident has 2 MAR entries for same drug. Diligent staff member (calls the system provider and) prevents patient harm.In this example the boxed medicine had wrong start date, which led to duplication duplication on the MAR chart. In a blister the dispenser would have noticed the start date error on one item and made the data entry correction prior to the box medicine reaching the patient bedside.

My advice on the subject of MDS vs OPD is that if you are being lobbied to change to original pack dispensing, here are some key questions to consider:

A. Bearing in mind that OPD could take twice as long, what are the advantages of moving to this? Can you be sure , for example that unsafe practices such as ‘potting up’ will not creep into use? Will it improve patient safety & compliance with NICE Guidelines and quality standards?

B. Ask for evidence on the benefits of OPD as opposed to MDS.

C. Ask for evidence to back up the claim that OPD will help reduce polypharmacy? (In my view this is a bizarre claim).

D. Ask for evidence to back up the claim  that OPD will reduce medicines waste.

E. Ask the residents or their families, or (if there’s an Lasting Power of Attorney [LPA] or Court of Protection order in place), ask the Attorneys or Deputys.

F. Ask the staff.

G. Ask the prescribers.

I’m interested in feedback on this. I am a nurse by trade and used to be a proponent of OPD in all circumstances. Since working in social care and with residential homes I’ve re-visited this view.

I now believe that care home residents need well designed systems and that, unless the patient can manage their medicines themselves (always the first consideration), a good MDS system is often a safer way to administer medicines.

4.2 . The benefits of using electronic MAR charts.

blister pack 3

These fall in to three categories.

  1. Improved legibility.
  2. Improved access (e.g. if the charts are accessed and updated on a computer or portable device there is less risk of losing, damaging  or mislaying them).
  3. eMAR chart systems that obtain the data taken directly from the Community Pharmacy system eliminate the need for transcribing, which is a high risk area.

In addition to the three benefits mentioned, carefully planned and  implemented eMAR systems contribute to a decrease in medicines errors, reduced administrative costs and improved quality of care.

Click here to read more about eMAR systems. Link:

tseUCsaH.jpg small

Author: Steve Turner, Managing Director Care Right Now CIC and Information Governance / Clinical Lead for CareMeds Ltd.

For information on our clinical review, professional development and teaching services contact: e:  m: 07931 919 330

Last updated: 05.09. 2019



Steve Turner is Data Protection Officer and Information Governance Lead for CareMeds Ltd.


and Head of Medicines & Prescribing @MedicineGov


Useful links:

NICE Guideline Managing Medicines in Care Homes

NICE Quality Standard Managing Medicines in Care Homes

CQC Managing Medicines in Health and Adult Social Care


Using technology in care homes – eMAR



Medicines errors in care homes are unacceptably high. A key study found that residents taking 7 or more medicines had a 79% chance of being victim of a medicines error (Alldred et all 2009).


Best practice in medicines record keeping

The management of medicines in nursing and residential homes is part of a highly complex pathway.  It involves multiple staff groups and organisations.

These include the G.P.; all who prescribe medicines and treatments; Care Staff of all grades; Support Workers; Consultants: Specialist Practitioners; and the Pharmacies who supply the medicines.

Benefits of electronic MAR charts

The benefits of implementing electronic MAR charts fall in to three categories.

  1. Improved legibility.
  2. Improved access (e.g. if the charts are accessed and updated on a computer or portable device there is less risk of losing, damaging  or mislaying them).
  3. eMAR chart systems that obtain the data taken directly from the Community Pharmacy system eliminate the need for transcribing, which is a high risk area.

In addition to the three benefits mentioned, carefully planned and  implemented eMAR systems contribute to a decrease in medicines errors, reduced administrative costs and improved quality of care.

Challenges of implementing electronic MAR charts

There are three ‘bottom line’ challenges to manage when transitioning to electronic MAR charts.

1. Assessing the way the system works is critical, as poorly designed will not deliver benefits, and eventually fail.

The system must be easy to use and jargon free; using only approved acronyms or mnemonics.

Electronic systems also offer the opportunity to introduce features which enhance safety, some of which, such as time ordered charts, are difficult to include in a paper based system.

Here’s a checklist:



2. It is vital that the system handles patient consent; patient confidentiality, system access; ownership of patient identifiable data; storage and transfer of data in a way which is compliant with the laws and regulations of your part of the U.K. This is an important question for you to pose to the supplier, particularly with the advent of General Data Protection Regulation (GDPR),  and the new Data Protection Act 2018.



3. It is important to look at current processes and how the new system will work. There been problems where acute prescriptions were needed and supplied by a different pharmacy from the one providing the MAR charts, so the home ended up at times with an electronic MAR and a paper MAR. This causes confusion and increases the risk of errors and/or omissions. Colleagues have told me of instances where this has led to eMAR systems being abandoned.

Training and support requirements

Quality training and support, both during the implementation and on an ongoing basis, underpin all successful healthcare I.T systems, and need to be planned from the outset. There are four areas which are sometimes overlooked, that deserve special mention.

1.  Many of the users of eMAR systems will be Healthcare Assistants or other non-registered skilled staff. As a result it will be important that the training they receive reinforces their duty to keep accurate records, and their accountability and role is made clear.

2. A significant number of staff may speak English as a second language. Therefore it is important that eMAR systems do not use any unnecessary jargon, and that any help text is in plain language.

3. Appropriate knowledge of Data Protection (GDPR) and Information Governance Rules and regulations are essential, and should be built in to any training programmes.

Overall, consideration needs to be given to the nature and content of the training needed to implement the system, including how this is linked to the policies and procedures and overall governance of the home.

Good suppliers will be able to give advice and support on this.


Record keeping in medicines management is a critical safety area for care homes. The current high level of medicines errors is in care homes affects the half a million people in England.

The prospect of implementing electronic systems for recording medicines administration holds great potential, but is not itself without risk. It needs to be approached carefully in the light of the complex arrangements and multiple organisations involved in prescribing, supplying, administering and monitoring medicines in care homes.

In time, electronic systems will become the norm for medicines management in care homes.

Given the considerations over choice and implementation of systems, eMAR can overcome problems of legibility, transcribing, and access to records and information in a way which is not possible with paper systems.

In years to come it is likely that, just as most G.P.’s would not want to return to paper systems, care homes will come to see electronic systems in the same way. The main beneficiary from this will be the residents in terms of improved safety.

This, in turn, will benefit care home staff who will no longer be involved in the risky business of sorting out, transcribing and chasing paper records. Care home providers will also benefit through decreased indirect costs associated with more efficient and safer processes.

Reference: Alldred P, Barber N, Buckle P et al (2009) Care home use of medicines study (CHUMS): Medication errors in nursing and residential care homes – prevalence, consequences, causes and solutions. Report to the Patient Safety Research Portfolio. Department of Health, London.
 Steve Turner is Information Governance Lead and Data Protection Officer for CareMeds Ltd

Managing Medicines in Care Homes. Implementing NICE Guidance and Quality Standards.


Managing Medicines in Care Homes. Communication and sharing medicines information. Implementing NICE Guidance and Quality Standards.

Steve Turner reflects on the communication challenges facing nursing and residential homes around implementing NICE Guidelines and Quality Standards, and offers some practical advice.

Quality Standards on managing medicines in care homes from the National Institute for Health and Care Clinical Excellence in England (NICE) link to the NICE Guidance on Managing Medicines in Care Homes, whch contains 118 recommendations.

This blog post offers suggestions on how to go about achieving the quality standards, focusing specifically on communication and timely sharing of accurate medicines information.

The findings are based on experiences of related quality improvement [QI] projects.

By working closely with front line staff in care homes, we have been able to identify and pilot some key changes. Then spread the learning.

As part of this approach we have produced an alternative checklist on managing medicine in care homes.
Managing medicines checklist:


By focusing on these questions at the outset, issues around best practice in medicines management can be identified.

These questions are particularly important due to the large number of people involved in the care of residents, which includes their G.P.; Specialist Nurses; Visiting Health Professionals; Pharmacists, Therapists, Hospitals and Outpatient Consultants.

Good quality management of medicines relies on all parties sharing information in a timely and auditable way. Much of this is outside the direct control of the care home.

Here’s two real life examples of things care homes can do to improve communication and promote best practice.

Example 1 – Knowledge of medicines and what they are being given for?

There are two main areas to consider here.

Knowledge of medicines:

Firstly, how much detail should staff know about the medicines residents are taking?

There are many medicines which need to be given in a specific way, e.g. with food, before food, after food, dependent on the pulse rate etc.

Often more specific instructions apply, such as for alendronic acid, which is usually given for osteoporosis. These tablets must be swallowed whole and the person taking the medicine must remain upright for a period of time afterwards. This is because the tablet is acidic and will damage the stomach wall if it doesn’t pass through it quickly. So if a resident is unable to take the tablet as directed, and therefore isn’t letting it pass through the stomach quickly, advice from a clinician as is needed straight away.

Another example of something where a basic knowledge of the medicine is needed is with the SSRI group of antidepressants (e.g. citalopram). Although these drugs aren’t addictive, they are medicines which need to be taken consistently and, if stopped abruptly (not tailed off), will often cause ‘discontinuation’ symptoms. These symptoms may include giddiness and very distressing feelings such as electric shock type sensations. If the resident isn’t able to express themselves easily their distress could be misinterpreted when they start to refuse to take it, or the supply has run out.

Information on each medicine is not always easily available. An answer to this is to ensure basic information leaflets on the medicines taken by residents are readily available to staff relatives and (wherever appropriate) to the resident, either in print, or on line. A good source of clearly written, short medicines information leaflets is available at .

Your local Pharmacy or Medicines Management Team, Specialist Nurses or G.P. will be able to give advice on the most appropriate patient information sheets, many of which are also available in easy read format and in other languages.

What are the medicines being given for?

Secondly, when giving out medicines, do staff, residents and relatives know what each medicine if being given for? NICE Guidance specifies that information on medicines and their indication (what they are being given for) should be readily available to all those involved in the management of medicines. In practice this isn’t an item which appears on most Medicines Administration Records (MAR charts). Neither is it always shown on the pharmacy label, which only lists exactly what the doctor has written on the prescription.

Why is this important? These differences can be significant, and lead to serious mistakes, if this information is missing.

Firstly, for completeness and good care I believe it’s unacceptable not to have this information readily to hand. All patients (and / or those caring for them, and acting on their behalf), whether this is in a care home or the person’s home, should be given this information, in order that the person (or their representative) can be part of a shared decision making process on the choice of medicines.

Secondly, visiting professionals and clinicians, out-of–hours and emergency services need to know this information in order to be able to assess and treat the residents safely. Many medicines can be given for different conditions often with a different dose range.

An example is amitriptyline which, if you look it up, is an anti-depressant; however it is also given in lower doses for neuropathic pain, and sometimes used for irritable bowel syndrome.

Another example is lithium which is frequently prescribed as a mood stabiliser, it can also be prescribed, in particular circumstances, to enhance the effect of anti-depressants. Unless the reason for the prescription is known and easy to find things can go wrong. I have known clinicians to stop lithium inappropriately because the records were incomplete.

When working as a Community Mental Health Nurse I once visited someone who had attempted suicide, who explained that she was driven to it because she was taking an antidepressant and it ‘wasn’t working’. In fact she had been prescribed amitriptyline for pain at a low dose, much lower than would be effective for depression.

In the longer term  shared electronic medicines records are the most appropriate and robust solution. Prior to this, there are a number of things which will  make the relevant information more readily available to all who need it.

At the risk of telling Granny how to suck eggs, here’s a checklist of interventions we are piloting as part of quality improvement projects:

1. Always query incomplete directions on medicines, either with the Pharmacy or the G.P.

2. When medicines are reviewed ask specifically for information on what they have been prescribed for, and record this.

3. Fax (or preferably email) medicines queries to G.P. Surgeries in order to keep a record of them. (This also means that people are not interrupted by ‘phone calls, don’t have to pass a verbal message on, and can consider the reply more fully.)

Example 2 – Records of communication between different services and professionals

Residents medicines are often managed by several professionals, for example the G.P. may prescribe based on information from a Psychiatrist, Specialist Nurse, Physiotherapist, Speech Therapist, Dietician, or Non-medical Prescribers may change, stop or add medicines themselves when they visit the home.

Residents may also be prescribed a variable dose drug such as warfarin, where the dose is monitored and prescribed by a separate service. Some residents may also be seeing private clinicians, or receiving alternative therapies which need to be known to other prescribers.

Diets and dietary supplements too must be communicated to all prescribers and this may have a significant effect on the absorption of medicines. The same is true for the resident’s posture, mobility and state of hydration, so all clinicians need to be aware of problems in these areas.

Complex information about medicines is frequently recorded is a variety of places, and these records are not always complete, particularly when something changes outside of the standard review cycle.

We’ve been looking at this more closely with staff in homes as part of an action learning process, and came up with the following recommendations:

1. If discharge information on medicines is incomplete raise this with the hospital concerned in writing, and (especially if this happens repeatedly) and ask for information on what will be done to correct this problem in the long term. This need is reinforced by a patient safety alert issued by NHS England on ‘timeliness of communication with primary and social care when patients are discharged from hospital’.

2. When visiting professionals carry out an assessment, and ask care home staff to contact the resident’s G.P., ask them to put this in writing. This avoids the possibility of mixed messages and enables a written record to be kept without duplication of effort.

3. When G.P.s visit the home to carry out reviews, prepare a structured written list of residents needing attention in advance of the visit.


Implementing Guidance and Quality Standards on medicines management in care homes can seem like a daunting task. By working closely with staff in the homes and starting out with some general questions, things which need to be changed can be identified and worked through in a systematic way.

Many of the difficulties around communication lie outside the direct control of the care home, as a result communication and information sharing need to be looked at jointly.

Residents benefit from the homes taking a lead in insisting on full medicines information from prescribers, to ensure safety. This involves remaining steadfastly assertive in pointing out when information is incomplete.

  • Key areas to focus on around communication are:
    • Does everyone (residents, staff, representatives and relatives) know what each medicine is being given for?
    • How are changes to medicines (i.e. starting, stopping, dose alterations and requests for reviews) communicated?

Author: Steve Turner                07931 919330 @MedicineGovSte

Steve is a nurse prescriber, Head of Medicines and Prescribing for @MedicineGov , Associate Lecturer at Plymouth University  and NICE Medicines and Prescribing Programme Associate.

mlkU-KY6.jpg large

Version 2 . Updated: 14.11.2018

Disruptive innovation works!



Being a disruptive innovator is hard to start with and may not fit into the standard tendering process, and you may appear to conflict with existing hierarchies.

Although I try to avoid jargon and avoid buzz words and fads, I think ‘disruptive innovation’ is probably a good description of work my Associates and I have been involved in.

You may find that the final product isn’t what you originally thought it was going to be, and it may take a long time for the beneficial changes to become accepted and spread.

In the end the benefits to patients and the public speak for themselves and it’s a hugely rewarding undertaking.

Some examples:

Childrens’ medicines safety

A successful interdisciplinary, multi-organisational prescribing project and the development of a parent held medicines record for children in the community with complex conditions.

0143_001 (2)

This work was published as a NICE shared learning example, was highly commended at the NICE Conference in 2005. It has had a lasting legacy.


Helping patients lead on their own care

My Associates and I have also developed, and successfully piloted, ‘patient led clinical medicines reviews’.


This novel approach involves medicines education session for patients, followed by the opportunity for people to review their medicines in a 3/4 hour session with two health professionals. It is published as a NICE shared learning example .

It’s listed on the NICE Shared Learning pages here:

I spoke on Managing care for patients with multimorbidities – case studies of implementing NICE guidance at the 2018 NICE Annual Conference.


Implementing safer prescribing in substance misuse

A successful inter-disciplinary project to implement non-medical prescribing across a substance misuse service. This project included developing and implementing an interdisciplinary / cross organisational medicine governance process.


This project was presented at the national NHS Change Day event in 2012 and published in the Nurse Prescribing Journal.

Ref: Introducing nurse prescribing in a substance misuse treatment service (Nov 4, 2012) Nurse Prescribing 2012 Vol1 10 No 11


Turning Up The Volume! for patient safety

In 2014 set up the Turn Up The Volume! patient safety movement, the aim of which is to promote best practice in patient safety through listening openly to concerns of patients, staff, carers and relatives, and taking actions together.


Dr Steve Bolsin talking at Turn Up The Volume! 2 London 2017

We have held two successfully open events and been influential in shaping NHS initiatives on ending the need for whistleblowing in relation to patient safety. I have presented on this at a number of national and local events, including a Health Education England ‘Future of Medical Education’ Conference in 2016 and at Barking Havering and Redbridge University Hospitals NHS Trust, as part of their dignity at work month.


Author: Steve Turner    07931 919 330   @MedicineGovSte

Join in with #MedLearn – and follow @MedicineGov


Version 2 : 09/07/2019